[go: up one dir, main page]

MX2007004893A - Metodos y composiciones para el tratamiento de leucemia linfocitica cronica. - Google Patents

Metodos y composiciones para el tratamiento de leucemia linfocitica cronica.

Info

Publication number
MX2007004893A
MX2007004893A MX2007004893A MX2007004893A MX2007004893A MX 2007004893 A MX2007004893 A MX 2007004893A MX 2007004893 A MX2007004893 A MX 2007004893A MX 2007004893 A MX2007004893 A MX 2007004893A MX 2007004893 A MX2007004893 A MX 2007004893A
Authority
MX
Mexico
Prior art keywords
lymphocytic leukemia
chronic lymphocytic
treating chronic
compositions
methods
Prior art date
Application number
MX2007004893A
Other languages
English (en)
Inventor
Januario E Castro
Thomas J Kipps
Francis J Burrows
Adeela Kamal
Carlo Prada
Original Assignee
Conforma Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conforma Therapeutics Corp filed Critical Conforma Therapeutics Corp
Publication of MX2007004893A publication Critical patent/MX2007004893A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Se describe un nuevo metodo para el tratamiento de leucemia linfocitica cronica mediante la administracion de inhibidores de HSP90, particularmente ansamicinas, mas en particular 17-alilamino-17-demetoxigetdanamicina (17-AAG).
MX2007004893A 2004-11-02 2005-11-02 Metodos y composiciones para el tratamiento de leucemia linfocitica cronica. MX2007004893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62463804P 2004-11-02 2004-11-02
PCT/US2005/039816 WO2006050457A2 (en) 2004-11-02 2005-11-02 Methods and compositions for treating chronic lymphocytic leukemia

Publications (1)

Publication Number Publication Date
MX2007004893A true MX2007004893A (es) 2007-06-14

Family

ID=36319809

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004893A MX2007004893A (es) 2004-11-02 2005-11-02 Metodos y composiciones para el tratamiento de leucemia linfocitica cronica.

Country Status (13)

Country Link
US (1) US20080280878A1 (es)
EP (1) EP1814392A4 (es)
JP (1) JP2008519031A (es)
KR (1) KR20070085677A (es)
CN (1) CN101072504A (es)
AU (1) AU2005302000A1 (es)
BR (1) BRPI0517268A (es)
CA (1) CA2584266A1 (es)
IL (1) IL182618A0 (es)
MX (1) MX2007004893A (es)
NO (1) NO20072190L (es)
RU (1) RU2007120473A (es)
WO (1) WO2006050457A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050333A2 (en) 2004-11-02 2006-05-11 The Regents Of The University Of California Methods and compositions for modulating apoptosis
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
AU2009208947B2 (en) 2008-02-01 2014-02-06 Takeda Pharmaceutical Company Limited Oxim derivatives as HSP90 inhibitors
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
CN102215689A (zh) * 2008-09-17 2011-10-12 鞘氨醇单胞菌研究合作伙伴有限合伙公司 白血病和特发性再生障碍性贫血的治疗
DE102008061214A1 (de) * 2008-12-09 2010-06-10 Merck Patent Gmbh Chinazolinamidderivate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021032A1 (en) * 1991-05-24 1992-11-26 The Regents Of The University Of California Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients
US6025126A (en) * 1991-10-28 2000-02-15 Arch Development Corporation Methods and compositions for the detection of chromosomal aberrations
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US6174875B1 (en) * 1999-04-01 2001-01-16 University Of Pittsburgh Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2468202A1 (en) * 2001-12-12 2003-06-19 Conforma Therapeutics Corporation Assays and implements for determining and modulating hsp90 binding activity
US20030194409A1 (en) * 2002-01-17 2003-10-16 Rothman James E. Conjugate heat shock protein-binding peptides
AU2003217393B8 (en) * 2002-02-08 2009-06-25 Conforma Therapeutics Corporation Ansamycins having improved pharmacological and biological properties
CA2413475C (en) * 2002-04-25 2010-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Zap-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll)
KR20050098244A (ko) * 2003-01-10 2005-10-11 쓰레솔드 파마슈티컬스, 인코포레이티드 2-데옥시글루코오스를 사용한 암 치료 방법
CA2539548A1 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
BRPI0418147A (pt) * 2003-12-23 2007-04-17 Infinity Pharmaceuticals Inc análogos de ansamicinas contendo benzoquinona e seus métodos de uso

Also Published As

Publication number Publication date
KR20070085677A (ko) 2007-08-27
CA2584266A1 (en) 2006-05-11
RU2007120473A (ru) 2008-12-10
CN101072504A (zh) 2007-11-14
AU2005302000A1 (en) 2006-05-11
BRPI0517268A (pt) 2008-10-07
EP1814392A2 (en) 2007-08-08
JP2008519031A (ja) 2008-06-05
US20080280878A1 (en) 2008-11-13
WO2006050457A3 (en) 2006-12-14
IL182618A0 (en) 2007-07-24
NO20072190L (no) 2007-07-13
WO2006050457A2 (en) 2006-05-11
EP1814392A4 (en) 2008-06-11

Similar Documents

Publication Publication Date Title
TNSN07196A1 (en) Potentiators of glutamate receptors
RS20060320A (en) Substituted indazole-o-glucosides
MY142777A (en) Substituted indole-o-glucosides
PL1682530T3 (pl) Podstawione pirolo-indole jako inhibitory PAI-1
UA87991C2 (en) Substituted indole-o-glucosides
MX2007007919A (es) Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
WO2005079756A3 (en) Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions
UA89226C2 (en) Imidazole compounds
MX2010007391A (es) Antagonistas de trpa1.
MX2010007392A (es) Antagonistas de trpa1.
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
TW200500361A (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
TW200624426A (en) BACE inhibitors
WO2007013997A3 (en) Inhibition of the raf/mek/p-erk pathway for treating cancer
TW200507840A (en) Method of treating multiple myeloma
NO20072190L (no) Fremgangsmater og sammensetninger for behandling av kronisk lymfatisk leukemi
MXPA05013151A (es) 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b.
TW200740460A (en) Pharmaceutical composition containing PPAR γ agonist
TW200716130A (en) Purified form of tanaproget
UA83203C2 (uk) Тіазол-(бі)циклоалкілкарбоксаніліди, засіб на їх основі та застосування для боротьби з небажаними мікроорганізмами
ZA202206266B (en) Pd-l1 antagonist compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal